Refine Technology and Gallus BioPharmaceuticals to Collaborate on Continuous BioManufacturing

Partners leverage knowledge to promote and expand continuous processing in the biotech industry

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Together, Refine and Gallus will be able to help these companies achieve their goals and deliver more robust quality and lower cost bioprocesses, building on the Gallus Center of Excellence for continuous processing for mammalian cell culture."

Pine Brook, NJ and St. Louis, MO, USA (PRWEB) January 22, 2013

Refine Technology, LLC (Refine), the developer and worldwide supplier to the biotech industry of the ATF™ System, a best-in-class cell retention device, and Gallus BioPharmaceuticals, LLC (Gallus), the industry leading contract bulk biopharmaceuticals manufacturer, today announced a collaboration to optimize continuous cell culture processes.

Gallus has already developed deep experience of Refine’s ATF System as the leading CMO in perfusion technology. Gallus uses the ATF System to manufacture a commercial antibody, StelaraTM, for J&J, which is distributed globally. Gallus looks to build upon this collaboration with Refine to expand the use of ATF System in perfusion, concentrated high cell density processes, and disposable processes.

“We are looking forward to deepening our involvement with Gallus, who are a skilled and flexible partner to work with,” stated Jerry Shevitz, President of Refine. “Many biopharmaceutical companies, both small and large, desire to move into high cell density and continuous production methods using our ATF System. Together, Refine and Gallus will be able to help these companies achieve their goals and deliver more robust quality and lower cost bioprocesses, building on the Gallus Center of Excellence for continuous processing for mammalian cell culture."

“With experience of developing over 40 molecules during a 26 year site history, combined with a decade of commercial manufacturing history, Gallus is strongly positioned to support clients to exploit the advantages of the ATF System in process development, clinical supply and commercial licensure for their products,” said Mark R. Bamforth, President & CEO at Gallus. “We are excited to expand Gallus’ leading technology partnerships by collaborating with Refine and their best-in-class technology.”

About Refine Technology
Refine Technology develops and commercializes equipment for the enhancement of cell culture processes. Its ATF System, which scales for use in the laboratory through to commercial manufacturing, has a range of uses from simple culture maintenance and perfusion, to generation of “extreme” cultures, to complex vaccine manufacturing. Refine Technology is dedicated to quality, customer support and providing solutions to a rapidly evolving biopharmaceutical industry. Based in New Jersey, USA, Refine Technology distributes and services its products worldwide through its network of highly trained sales and support personnel.

About Gallus Biopharmaceuticals
Gallus BioPharmaceuticals is a leading contract manufacturing company offering exceptional contract services to its clients. The firm, based in St. Louis, Mo., was established in 2010 and acquired a world-class commercial biopharmaceutical manufacturing facility and workforce from Johnson & Johnson/Centocor division in 2011. In addition to process development and clinical supply services, Gallus currently produces two commercial products that are distributed globally. The St. Louis facility has been inspected by every major regulatory body worldwide. For additional information on biopharmaceutical contract development and manufacturing services, visit http://www.gallusbiopharma.com, email info(at)gallusbiopharma(dot)com or call directly at (314) 426-5000.


Contact

Follow us on: Contact's Facebook Contact's LinkedIn